Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Germline variants of homology-directed repair or mismatch repair genes in cervical cancer () Kokemüller L, Ramachandran D, Schürmann P, Geffers R, Jentschke M, Böhmer G, Strauß HG, et al. Journal article Effect of delayed isolation of peripheral blood mononuclear cells on cell viability and functionality (2025) Lehle S, Völkl S, Seitz K, Goossens C, Emons J, Rübner M, Uhrig S, et al. Journal article Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer (2025) Hoppe R, Winter S, Lo WY, Michailidou K, Bolla MK, Keeman R, Wang Q, et al. Journal article Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis (2025) Fu Z, Borho L, Taylor SE, Kelemen LE, DeFazio A, Webb PM, Köbel M, et al. Journal article Treatment of Patients with Early Breast Cancer 19th St. Gallen International Breast Cancer Consensus Discussed against the Background of German Treatment Recommendations Behandlung von Patientinnen mit fruhem Mammakarzinom 19. Internationaler St..Gallen.Konsens vor dem Hintergrund deutscher Therapieempfehlungen diskutiert (2025) Untch M, Banys-Paluchowski M, Brucker SY, Denkert C, Fasching P, Haidinger R, Harbeck N, et al. Journal article, Review article Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study (2025) Decker T, Brucker C, Engel A, Fasching P, Göhler T, Jackisch C, Janssen J, et al. Journal article Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer (2025) O'Shaughnessy J, Tolaney SM, Yardley DA, Hart L, Razavi P, Fasching P, Janni W, et al. Journal article Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk (2025) Müller V, Hörner M, Thill M, Banys-Paluchowski M, Schmatloch S, Fasching P, Harbeck N, et al. Journal article The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study (2025) Schneeweiss A, Fasching P, Thill M, van Mackelenbergh M, Marme F, Tesch H, Fehm TN, et al. Journal article Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer (2025) Lüftner D, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Journal article, Review article